Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prostate cancer: diagnostic performance of the PCA3 urine test.

Literature DB >> 21394175

Prostate cancer: diagnostic performance of the PCA3 urine test.

George Leighton Lee, Albert Dobi, Shiv Srivastava.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2011 PMID： 21394175 DOI： 10.1038/nrurol.2011.10

Source DB: PubMed Journal: Nat Rev Urol ISSN： 1759-4812 Impact factor: 14.432

× No keyword cloud information.

9 in total

Review 1. PCA3: from basic molecular science to the clinical lab.

Authors: John R Day; Matthias Jost; Mark A Reynolds; Jack Groskopf; Harry Rittenhouse
Journal: Cancer Lett Date: 2010-11-18 Impact factor: 8.679

2. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome.

Authors: Marco Auprich; Alexander Haese; Jochen Walz; Karl Pummer; Alexandre de la Taille; Markus Graefen; Theo de Reijke; Margit Fisch; Paul Kil; Paolo Gontero; Jacques Irani; Felix K-H Chun
Journal: Eur Urol Date: 2010-07-03 Impact factor: 20.096

3. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?

Authors: Guillaume Ploussard; Alexander Haese; Hendrik Van Poppel; Michael Marberger; Arnulf Stenzl; Peter F A Mulders; Hartwig Huland; Laurence Bastien; Clèment-Claude Abbou; Mesut Remzi; Martina Tinzl; Susan Feyerabend; Alexander B Stillebroer; Martijn P M Q Van Gils; Jack A Schalken; Alexandre de La Taille
Journal: BJU Int Date: 2010-10 Impact factor: 5.588

4. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.

Authors: Leonard S Marks; Yves Fradet; Ina Lim Deras; Amy Blase; Jeannette Mathis; Sheila M J Aubin; Anthony T Cancio; Marie Desaulniers; William J Ellis; Harry Rittenhouse; Jack Groskopf
Journal: Urology Date: 2007-03 Impact factor: 2.649

5. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.

Authors: M J Bussemakers; A van Bokhoven; G W Verhaegh; F P Smit; H F Karthaus; J A Schalken; F M Debruyne; N Ru; W B Isaacs
Journal: Cancer Res Date: 1999-12-01 Impact factor: 12.701

6. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test.

Authors: Monique J Roobol; Fritz H Schröder; Pim van Leeuwen; Tineke Wolters; Roderick C N van den Bergh; Geert J L H van Leenders; Daphne Hessels
Journal: Eur Urol Date: 2010-07-09 Impact factor: 20.096

7. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.

Authors: Alexander Haese; Alexandre de la Taille; Hendrik van Poppel; Michael Marberger; Arnulf Stenzl; Peter F A Mulders; Hartwig Huland; Clément-Claude Abbou; Mesut Remzi; Martina Tinzl; Susan Feyerabend; Alexander B Stillebroer; Martijn P M Q van Gils; Jack A Schalken
Journal: Eur Urol Date: 2008-06-26 Impact factor: 20.096

Review 8. Urine biomarkers in prostate cancer.

Authors: Guillaume Ploussard; Alexandre de la Taille
Journal: Nat Rev Urol Date: 2010-01-12 Impact factor: 14.432

9. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.

Authors: Daphne Hessels; Jacqueline M T Klein Gunnewiek; Inge van Oort; Herbert F M Karthaus; Geert J L van Leenders; Bianca van Balken; Lambertus A Kiemeney; J Alfred Witjes; Jack A Schalken
Journal: Eur Urol Date: 2003-07 Impact factor: 20.096

9 in total

72 in total

Prostate cancer: diagnostic performance of the PCA3 urine test.

Review 1. PCA3: from basic molecular science to the clinical lab.

2. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome.

3. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?

4. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.

5. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.

6. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test.

7. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.

Review 8. Urine biomarkers in prostate cancer.

9. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.

1. Plasma long noncoding RNA protected by exosomes as a potential stable biomarker for gastric cancer.

Review 2. Noncoding RNAs involved in mammary gland development and tumorigenesis: there's a long way to go.

Review 3. Long non-coding RNAs and cancer: a new frontier of translational research?

4. Translational genomics: the challenge of developing cancer biomarkers.

Review 5. Regulation of mammary epithelial cell homeostasis by lncRNAs.

Review 6. Minireview: Long noncoding RNAs: new "links" between gene expression and cellular outcomes in endocrinology.

Review 7. Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

8. Highlights from the prostate cancer genome report.

Review 9. From discovery to function: the expanding roles of long noncoding RNAs in physiology and disease.

10. Using the epigenetic field defect to detect prostate cancer in biopsy negative patients.